InsiderTrades.com logo
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

PCSA Insider Trading

Insider Ownership Percentage: 22.20%
Insider Buying (Last 12 Months): $52,000.00
Insider Selling (Last 12 Months): $0.00

Processa Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Processa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Processa Pharmaceuticals Share Price & Price History

Current Price: $0.48
Price Change: ▲ Price Increase of +0.01 (2.15%)
As of 11/28/2023 01:00 AM ET

This chart shows the closing price history over time for PCSA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

Processa Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2023David YoungCEOBuy40,000$0.80$32,000.00470,424View SEC Filing Icon  
4/13/2023David YoungCEOBuy20,000$0.48$9,600.00410,424View SEC Filing Icon  
4/11/2023David YoungCEOBuy20,000$0.52$10,400.00370,424View SEC Filing Icon  
5/17/2022Patrick LinInsiderBuy2,000$1.59$3,180.00433,390View SEC Filing Icon  
4/6/2022Patrick LinInsiderBuy1,200$3.13$3,756.00431,390View SEC Filing Icon  
1/27/2022Justin W. YorkeDirectorSell1,854$3.30$6,118.20View SEC Filing Icon  
12/14/2021Patrick LinInsiderBuy3,000$4.00$12,000.00View SEC Filing Icon  
12/6/2021Justin W. YorkeDirectorSell4,200$4.71$19,782.00View SEC Filing Icon  
12/3/2021Justin W. YorkeDirectorSell5,500$4.84$26,620.00View SEC Filing Icon  
12/3/2021Patrick LinInsiderBuy3,500$4.80$16,800.00View SEC Filing Icon  
8/26/2021Patrick LinInsiderBuy4,000$6.02$24,080.00422,890View SEC Filing Icon  
6/23/2021David YoungCEOBuy10,000$7.67$76,700.00345,190View SEC Filing Icon  
6/22/2021Robert Michael FloydCOOBuy2,000$7.03$14,060.0028,000View SEC Filing Icon  
6/21/2021James H. StankerCFOBuy1,000$6.81$6,810.0036,510View SEC Filing Icon  
4/13/2021Justin W. YorkeDirectorSell6,500$9.86$64,090.00300,706View SEC Filing Icon  
4/13/2021Justin W. YorkeDirectorSell6,500$9.86$64,090.00300,706View SEC Filing Icon  
4/8/2021James E BesserInsiderSell400,000$10.76$4,304,000.001,064,300View SEC Filing Icon  
4/6/2021James E BesserInsiderSell31,771$10.91$346,621.611,064,300View SEC Filing Icon  
2/22/2021James E BesserMajor ShareholderSell20,929$11.56$241,939.241,120,000View SEC Filing Icon  
2/18/2021James E BesserMajor ShareholderSell5,000$11.35$56,750.001,120,000View SEC Filing Icon  
See Full Table
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Processa Pharmaceuticals (NASDAQ:PCSA)

5.67% of Processa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PCSA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Processa Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/21/2023Walleye Capital LLC419,277$0.11M0.0%+14.4%1.702%Search for SEC Filing on Google Icon
8/15/2023Walleye Capital LLC366,637$0.18M0.0%-50.0%1.495%Search for SEC Filing on Google Icon
8/15/2023Citadel Advisors LLC282,837$0.14M0.0%N/A1.153%Search for SEC Filing on Google Icon
5/15/2023Two Sigma Securities LLC62,626$31K0.0%N/A0.255%Search for SEC Filing on Google Icon
2/8/2023Raymond James Financial Services Advisors Inc.48,951$54K0.0%N/A0.306%Search for SEC Filing on Google Icon
11/10/2022Dimensional Fund Advisors LP12,466$28K0.0%N/A0.079%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC11,600$33K0.0%N/A0.073%Search for SEC Filing on Google Icon
8/5/2022Coastal Bridge Advisors LLC52,500$0.15M0.0%+61.5%0.331%Search for SEC Filing on Google Icon
2/15/2022Coastal Bridge Advisors LLC32,500$0.16M0.0%+18.2%0.207%Search for SEC Filing on Google Icon
2/10/2022AIGH Capital Management LLC303,703$1.49M0.5%-21.5%1.932%Search for SEC Filing on Google Icon
1/26/2022Verdence Capital Advisors LLC63,227$0.31M0.0%-14.3%0.402%Search for SEC Filing on Google Icon
10/29/2021Janney Montgomery Scott LLC46,231$0.40M0.0%-18.5%0.296%Search for SEC Filing on Google Icon
8/16/2021State Street Corp16,600$0.14M0.0%N/A0.107%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC37,400$0.31M0.0%+34.4%0.240%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.373,171$3.06M0.0%+136.7%2.397%Search for SEC Filing on Google Icon
8/10/2021Coastal Bridge Advisors LLC27,500$0.23M0.0%+37.5%0.177%Search for SEC Filing on Google Icon
8/9/2021Vectors Research Management LLC4,000$33K0.0%N/A0.026%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC13,117$0.14M0.0%N/A0.085%Search for SEC Filing on Google Icon
5/19/2021Worth Venture Partners LLC90,968$0.94M0.5%N/A0.586%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC93,999$1.03M0.0%-12.0%0.606%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC13,117$0.14M0.0%N/A0.085%Search for SEC Filing on Google Icon
5/17/2021Coastal Bridge Advisors LLC20,000$0.22M0.0%N/A0.129%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp12,845$0.14M0.0%N/A0.083%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC27,825$0.30M0.0%N/A0.179%Search for SEC Filing on Google Icon
5/12/2021Essex Investment Management Co. LLC72,908$0.80M0.1%-2.7%0.470%Search for SEC Filing on Google Icon
5/4/2021Commonwealth Equity Services LLC10,550$0.12M0.0%N/A0.068%Search for SEC Filing on Google Icon
4/27/2021Janney Montgomery Scott LLC63,331$0.69M0.0%-4.5%0.408%Search for SEC Filing on Google Icon
2/13/2021Essex Investment Management Co. LLC74,928$0.49M0.1%N/A0.709%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Processa Pharmaceuticals logo
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.
Read More on Processa Pharmaceuticals

Today's Range

Now: $0.48
Low: $0.45
High: $0.50

50 Day Range

MA: $0.35
Low: $0.18
High: $0.61

52 Week Range

Now: $0.48
Low: $0.18
High: $2.24

Volume

458,828 shs

Average Volume

475,375 shs

Market Capitalization

$11.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11

Who are the company insiders with the largest holdings of Processa Pharmaceuticals?

Processa Pharmaceuticals' top insider investors include:
  1. David Young (CEO)
  2. Patrick Lin (Insider)
  3. Justin W Yorke (Director)
Learn More about top insider investors at Processa Pharmaceuticals.

Who are the major institutional investors of Processa Pharmaceuticals?

Processa Pharmaceuticals' top institutional investors include:
  1. Walleye Capital LLC — 1.70%
Learn More about top institutional investors of Processa Pharmaceuticals stock.

Which institutional investors are buying Processa Pharmaceuticals stock?

Within the last quarter, PCSA stock was bought by institutional investors including:
  1. Walleye Capital LLC
Within the previous year, these company insiders have bought Processa Pharmaceuticals stock:
  1. David Young (CEO)
  2. Patrick Lin (Insider)
Learn More investors buying Processa Pharmaceuticals stock.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.